Results 121 to 130 of about 648 (164)
Some of the next articles are maybe not open access.
Diroximel Fumarate in the Treatment of Multiple Sclerosis
Neurodegenerative Disease Management, 2020Diroximel fumarate (DRF) is a new emerging therapy for patients with multiple sclerosis. The levels of its active metabolite, monomethyl fumarate, are bioequivalent to the levels generated from dimethyl fumarate (DMF) treatment. The efficacy and safety profiles of DRF are expected to be similar to the well-established profiles of DMF. The metabolism of
Elise Jonasson, Tobias Sejbaek
openaire +4 more sources
Diroximel fumarate to treat multiple sclerosis
Drugs of Today, 2020On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl fumarate (DMF), was approved for the same indication on March 27, 2013.
Y, Wang, P, Bhargava
openaire +2 more sources
CNS Drugs, 2023
Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus PON or TERI.The objectives of this analysis were to compare DRF versus PON and DRF versus TERI for clinical and radiological outcomes.We used ...
Tammy Jiang +7 more
openaire +2 more sources
Diroximel fumarate (DRF), ponesimod (PON), and teriflunomide (TERI) are oral disease-modifying therapies approved for the treatment of relapsing multiple sclerosis. No randomized trials have compared DRF versus PON or TERI.The objectives of this analysis were to compare DRF versus PON and DRF versus TERI for clinical and radiological outcomes.We used ...
Tammy Jiang +7 more
openaire +2 more sources
Diroximel fumarate – a new twist for MS agent best seller
Progress in Neurology and Psychiatry, 2022Fast track appraisal (FTA) was adopted by NICE in 2017. This faster and more simplified process is mainly used for novel pharmaceutical agents that are considered bioequivalent to an already recommended drug with added advantages or reduced costs. In June 2022 NICE used FTA to recommend diroximel fumarate (Vumerity) for the management of relapsing ...
openaire +1 more source
Diroximel Fumarate in Relapsing Forms of Multiple Sclerosis: A Profile of Its Use
CNS Drugs, 2021Diroximel fumarate (Vumerity®), an orally administered disease-modifying drug (DMD), expands the available treatment options for adults with relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting MS (RRMS), and active secondary progressive MS.
openaire +2 more sources
Multiple Sclerosis and Related Disorders
Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are similar disease-modifying therapies (DMTs) that reduce disease activity in patients with relapsing-remitting multiple sclerosis (MS). We expect that patients on DRF would experience a similar incidence and severity of lymphopenia, given that it is a well-documented side effect of DMF treatment.We
John Patrick Dempsey +5 more
openaire +2 more sources
Diroximel fumarate (DRF) and dimethyl fumarate (DMF) are similar disease-modifying therapies (DMTs) that reduce disease activity in patients with relapsing-remitting multiple sclerosis (MS). We expect that patients on DRF would experience a similar incidence and severity of lymphopenia, given that it is a well-documented side effect of DMF treatment.We
John Patrick Dempsey +5 more
openaire +2 more sources
BMJ Case Reports
We present a case of a woman in her 50s with relapsing-remitting multiple sclerosis, treated with diroximel fumarate, who developed an itching, burning vesicular rash following a C3 dermatomal distribution on her left face and neck. She was diagnosed with herpes zoster, treated with valacyclovir and gabapentin, and made a full recovery.
John Dempsey +2 more
openaire +2 more sources
We present a case of a woman in her 50s with relapsing-remitting multiple sclerosis, treated with diroximel fumarate, who developed an itching, burning vesicular rash following a C3 dermatomal distribution on her left face and neck. She was diagnosed with herpes zoster, treated with valacyclovir and gabapentin, and made a full recovery.
John Dempsey +2 more
openaire +2 more sources
Clinical Drug Investigation
Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). However, no real-world study to date has significantly addressed the efficacy of this treatment.This study aims to elucidate the safety, tolerability, and efficacy of DRF in a real-world ...
Clara, Aguirre +30 more
openaire +2 more sources
Current literature and a real-world study suggest that diroximel fumarate (DRF) is safer than dimethyl fumarate (DMF) in the treatment of multiple sclerosis (MS). However, no real-world study to date has significantly addressed the efficacy of this treatment.This study aims to elucidate the safety, tolerability, and efficacy of DRF in a real-world ...
Clara, Aguirre +30 more
openaire +2 more sources